Intracellular Targeted Drug Delivery Market Size (2023 - 2030)

Global Intracellular Targeted Drug Delivery Market is estimated to be worth USD 2.32 Billion in 2022 and is projected to reach a value of USD 7.87 Billion by 2030, growing at a CAGR of 16.5% during the forecast period 2023-2030.

Intracellular targeted drug delivery entails directly delivering drugs or active substances into the interior of cells. The core purpose of targeted drug delivery is to specifically target diseased cells while sparing healthy cells. The methods utilized for intracellular drug delivery can differ depending on the specific drug and delivery system employed. Common mechanisms include direct internalization and endocytosis. Various factors, such as the targeting component, target receptor, size, shape, and surface properties of the drug carrier, influence the successful delivery of drugs within cells. Intracellular targeted drug delivery is vital in various medical treatments, encompassing cell-based therapies, gene editing, and targeted drug delivery systems. Nonetheless, there are obstacles to address, such as barriers within cells, inconsistent uptake, unintended effects on non-targeted areas, restricted targeting choices, and potential toxicity. Scientists are actively experimenting and devising novel methods and technologies to elevate the efficiency and accuracy of intracellular targeted drug delivery.

Global Intracellular Targeted Drug Delivery Market Drivers:

The rising incidence of chronic diseases is fueling the growth of the Global Intracellular Targeted Drug Delivery Market.

The global surge in chronic health conditions like cardiovascular diseases, oncological disorders, endocrine diseases, infectious diseases, and pulmonary diseases has sparked an augmented demand for intracellular targeted drug delivery systems. Intracellular targeted drug delivery is a method that delivers drugs directly to diseased cells, which minimizes damage to healthy cells and lowers toxicity. By precisely targeting specific compartments within diseased cells, this technique enhances the efficacy of treatment. It also improves drug circulation in the body, which enables sustained release and prolonged exposure to diseased cells. Therefore, this factor propels the demand for intracellular targeted drug delivery systems.

The growing patient preference for advanced healthcare products is another factor contributing to the growth of the Global Intracellular Targeted Drug Delivery Market.

The healthcare industry is witnessing a growing preference for cutting-edge products among patients. Factors propelling this trend include reduced variability in systemic drug concentrations, precise drug delivery to specific sites, and the popularity of self-administered devices. For instance, Idorsia and Antares collaborated to create a self-administered drug device product. Digitalization of medical devices has also increased patient awareness, offering benefits like needle-free injections and controlled dosage. Recently, Medtronic plc launched Efficio, a cloud-based software managing targeted drug delivery for chronic pain and other conditions. With patient demand for advanced products and government initiatives promoting awareness, the market is projected to experience significant growth in the future.

Global Intracellular Targeted Drug Delivery Market Challenges:

The Global Intracellular Targeted Drug Delivery Market is encountering challenges, primarily in terms of cost and reimbursement. Devising and commercializing intracellular targeted drug delivery systems can be pricy. It can be difficult to substantiate that these systems are high-priced and secure reimbursement from healthcare systems or insurance providers, especially in markets with fierce competition. The financial outlays and reimbursement challenges may have an impact on how extensively these systems are adopted and their overall viability. Thus, these challenges inhibit the growth of the Global Intracellular Targeted Drug Delivery Market.

Global Intracellular Targeted Drug Delivery Market Opportunities:

Market expansion strategies present a lucrative opportunity in the Global Intracellular Targeted Drug Delivery Market. The demand for intracellular targeted drug delivery systems is augmenting owing to their advantages, including increased efficacy, reduced toxicity, enhanced pharmacokinetics, improved specificity, and lowered dosing frequency. Businesses specializing in the production of intracellular targeted drug delivery systems can attain considerable benefits from this opportunity by broadening their product offerings to emerging markets, encompassing China, India, Brazil, and Mexico. By pursuing this expansion, companies can broaden their customer base and drive a notable increase in their overall revenue.

COVID-19 Impact on the Global Intracellular Targeted Drug Delivery Market:

The Global Intracellular Targeted Drug Delivery Market has been considerably influenced by the COVID-19 outbreak. The market suffered significant upheavals and delays in clinical trials due to rigorous lockdowns, travel restrictions, and social distancing measures. The pandemic redirected resources towards COVID-19 therapies, which impacted intracellular targeted drug delivery research for other diseases. Furthermore, the economic consequences of the pandemic led to financial constraints and diminished capital allocation across multiple sectors, including drug development. These factors negatively impacted the market's growth. Despite these challenges, the market is projected to rebound alongside the global recovery from the pandemic.

Global Intracellular Targeted Drug Delivery Market Recent Developments:

• In May 2023, CPI, an innovation organization, unveiled collaborations with Medicines Discovery Catapult, the University of Strathclyde, the University of Liverpool, and Imperial College London to set up a new Intracellular Drug Delivery Centre. The purpose of establishing this center is to advance the development of innovative drug delivery technologies and provide support for promising RNA vaccines and therapeutics.

• In April 2023, UK biotech company Vitarka Therapeutics raised GBP 1.27 million in funding from SOSV, UK12S, and Innovate UK. Specializing in non-viral drug delivery technology, Vitarka Therapeutics strives to revolutionize the industry and attain significant breakthroughs in the field.

• In October 2022, Orum Therapeutics, a private biotech company, unveiled the initiation of a Phase 1 clinical trial where the first patient received ORM-5029. This trial is focused on patients with advanced solid tumors expressing HER2. ORM-5029 is a crucial element of Orum Therapeutics' GSPT1 platform, employing an innovative method called Dual-Precision Targeted Protein Degradation (TPD²). By utilizing antibody-drug conjugates (ADCs), this approach precisely targets and delivers proteins to cancer cells, which leads to their degradation and subsequent cancer cell death.

INTRACELLULAR TARGETED DRUG DELIVERY MARKET REPORT COVERAGE:

Global Intracellular Targeted Drug Delivery Market Segmentation: By Disease Type

• Cardiovascular Diseases

• Endocrine Diseases

• Infectious Diseases

• Oncological Disorders

• Pulmonary Diseases

The Oncological Disorders segment occupied the highest market share in the year 2022. The growth can be ascribed to the utilization of intracellular targeted drug delivery, which permits drugs to be delivered directly to cancer cells while curbing deleterious effects on healthy cells and attenuating toxicity. By precisely delivering drugs to specific compartments within cancer cells, such as the mitochondria or nucleus, this approach strengthens the effectiveness of cancer treatment. Furthermore, intracellular targeted drug delivery boosts the circulation of drugs in the body, which enables sustained release and prolonged exposure to cancer cells. Consequently, intracellular targeted drug delivery shows great potential in enhancing the effectiveness and safety of cancer treatments.

Global Intracellular Targeted Drug Delivery Market Segmentation: By End User

• Clinics

• Hospitals

• Others

The Hospitals segment occupied the highest market share in the year 2022. The growth can be ascribed to hospitals being primarily focused on efficiently serving a larger number of patients, which contributes significantly to the market revenue. Hospitals generally possess cutting-edge medical infrastructure and facilities, encompassing specialized equipment and laboratories. These resources empower hospitals to effectively incorporate intracellular targeted drug delivery systems and perform essential tests and procedures. There is an augmenting demand for bulk medications specifically devised for intracellular targeted drug administration. Hospitals, owing to their larger patient volume compared to clinics and other medical facilities, witness the highest number of individuals seeking medical treatment.

Global Intracellular Targeted Drug Delivery Market Segmentation: By Region

• North America

• Europe

• Asia-Pacific

• South America

• Middle East & Africa

The region of North America dominated the Global Intracellular Targeted Drug Delivery Market in the year 2022. The rising incidence of oncological disorders among individuals, the presence of well-established healthcare infrastructure in nations, such as the United States and Canada, the proliferating advancements in drug delivery systems, and the increasing investments in research and development activities are some of the pivotal factors propelling the region's growth. Furthermore, North America is home to several prominent market players, including Pfizer Inc., AbbVie Inc., Arrowhead Pharmaceuticals, Inc., Seagen Inc., and CytImmune Sciences Inc. The region of Asia-Pacific is anticipated to expand at the quickest rate over the forecast period 2023-2030 owing to the augmenting demand for various applications, including catheters & cannulas, drug delivery systems, bulk targeted drug delivery and specialized applications like smoke evacuation tubing and peristaltic pump tubing, the increasing accessibility to healthcare services, and the rising popularity of minimally invasive medical procedures.

Global Intracellular Targeted Drug Delivery Market Key Players:

1. Pfizer Inc. (United States)

2. AbbVie Inc. (United States)

3. Novartis AG (Switzerland)

4. Arrowhead Pharmaceuticals, Inc. (United States)

5. AstraZeneca PLC (United Kingdom)

6. ADC Therapeutics SA (Switzerland)

7. F. Hoffmann-La Roche AG (Switzerland)

8. Nanobiotix SA (France)

9. Seagen Inc. (United States)

10. CytImmune Sciences Inc. (United States)